Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Diagnostics Reg Reform Draft Proposes Pathways For Relaxed Scrutiny

This article was originally published in The Gray Sheet

Executive Summary

A House Subcommittee plans to take up draft legislation at a hearing next month that brings together test kits and lab-developed tests into a new regulatory category. The proposal offers many ways for tests to avoid a “high-risk” classification. “The Gray Sheet” compares the provisions to recent proposals vetted in the Senate.

Advertisement

Related Content

Diagnostics Reg Overhaul Floated In US House
What's Next For LDTs? FDA May Be Eyeing A New Game Plan
Don't Finalize LDT Guidance, House Appropriators Tell FDA
Lab Group Urges FDA To Wait For Congress On LDT Issue
CMS And FDA Stand Together Behind FDA Oversight Of LDTs At House Hearing
On Eve Of House Hearing, FDA Makes Its Case For LDT Framework
Congress Will Not Tinker With FDA LDT Guidance Before Final, Staffers Indicate
Molecular Pathologists Propose Third-Party Review Of High-Risk Dx In Alternative To FDA LDT Plan
Senators Circulate Plan For Standalone FDA Diagnostics Center, ‘In Vitro Clinical Test’ Rules
FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT034333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel